Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Geographic Opportunistic Infections of Specific Consideration
Last Updated: May 7, 2013; Last Reviewed: September 13, 2017
NOTE: Update in Progress
Penicilliosis is caused by the dimorphic fungus Penicillium marneffei, which is known to be endemic in Southeast Asia (especially Northern Thailand and Vietnam) and southern China.1-3 More recently, indigenous cases of penicilliosis have been seen in several states of India, particularly Manipur, which is a new endemic area for this fungus.4-6
Before the era of antiretroviral therapy (ART), penicilliosis was the presenting AIDS-defining illness in 6.8% of HIV-infected patients from the northern provinces of Thailand and less common elsewhere.7 Most cases of penicilliosis are observed in patients who have CD4 T lymphocyte (CD4) cell counts <100 cells/mm3.8 The infection is associated with a high mortality rate if timely treatment with appropriate antifungal drugs is not administered.9
No data are available on acquisition and transmission of penicilliosis. However, like histoplasmosis, it is believed to be acquired by inhalation of microconidia from the mycelial phase of the organism. Reactivation of a silent focus of infection that was acquired years earlier can occur when cellular immunity wanes and it is the presumed mechanism for disease occurrence in nonendemic areas. Evidence exists for seasonality in penicilliosis infections; increased cases have been noted during the rainy months.10,11
The common clinical manifestations include fever, anemia, weight loss, and generalized skin papules with central umbilication resembling molluscum contagiosum.1,5 Cutaneous penicilliosis lesions commonly appear on the face, ears, extremities, and occasionally the genitalia. Involvement of other organs, such as the central nervous system, bone marrow, lymph node, lung, liver, and intestine, has been reported. Patients with hepatic penicilliosis have fever, abdominal pain, hepatomegaly, and a marked increase in serum alkaline phosphatase levels.3
The definitive diagnosis of penicilliosis is based on isolation of organisms from cultures of blood or other clinical specimens or by histopathologic demonstration of organisms in biopsy material. P. marneffei exibits dimorphic growth in culture. At 25oC, the fungus grows as a mold, demonstrating characteristic colonies that include a flat green surface and underlying deep red coloring. At 37oC the fungus grows as white colonies of yeast.12
An early presumptive diagnosis can be made several days before the results of fungal cultures are available by microscopic examination of Wright-stained samples of skin scrapings, bone marrow aspirate, or lymph node biopsy specimens. Many intracellular and extracellular basophilic, spherical, oval, and elliptical yeast-like organisms can be seen, some with clear central septation, which is a characteristic feature of P. marneffei.1,5 In some patients, the fungus can be identified by microscopic examination of a Wright’s-stained peripheral blood smear.13
Available information does not support specific recommendations regarding exposure avoidance. However, patients with advanced HIV disease should avoid visiting endemic areas, and particularly rural areas in those regions (BIII).
A double-blind, placebo-controlled study from Chiang Mai, Thailand, demonstrated that oral itraconazole, 200 mg daily for primary prophylaxis, significantly reduced occurrence of systemic fungal infections (cryptococcosis and penicilliosis) in HIV-infected patients with CD4 counts <200 cells/mm3.8 Fluconazole may also be effective prophylaxis.14 For most patients from the United States, such primary prophylaxis would only be indicated in unusual situations in which those who are highly immunosuppressed have to travel to high-risk areas.
Indication for Primary Prophylaxis
All HIV-infected patients with CD4 counts <100 cells/mm3 who reside or stay for a long period in northern Thailand, Vietnam, and southern China, and particularly in rural areas, should be administered primary prophylaxis (BI). The preferred drug for prophylaxis is oral itraconazole, 200 mg/day (BI). An alternative drug is oral fluconazole 400 mg once weekly (BII). Primary prophylaxis is not indicated in other geographic areas.15
Discontinuation of Primary Prophylaxis
No randomized, controlled study has demonstrated the safety of discontinuation of primary prophylaxis for penicilliosis. However, a retrospective cohort study reported no relapse in penicilliosis and invasive fungal infections after discontinuation of itraconazole in patients receiving ART who had CD4 counts >100 cells/mm3.16 Therefore, primary prophylaxis for penicilliosis can logically be discontinued in AIDS patients who receive combination ART and have CD4 counts >100 cells/mm3 for ≥6 months but there are no convincing data addressing this issue (CII). Primary prophylaxis should be reintroduced if the CD4 count decreases to <100 cells/mm3 (BIII).
The recommended treatment is liposomal amphotericin B, 3 to 5 mg/kg body weight/day intravenously for 2 weeks, followed by oral itraconazole, 400 mg/day for a subsequent duration of 10 weeks (AII), followed by secondary prophylaxis.17 Patients with mild disease can be initially treated with oral itraconazole 400 mg/day for 8 weeks (BII),18 followed by 200 mg/day for prevention of recurrence. Itraconazole capsule is better absorbed when taken with or immediately after a meal. Itraconazole oral solution can be taken on an empty stomach.
The alternative drug for primary treatment in the hospital is IV voriconazole, 6 mg/kg every 12 hours on day 1 and then 4 mg/kg every 12 hours for at least 3 days, followed by oral voriconazole, 200 mg twice daily for a maximum of 12 weeks. Patients with mild disease can be initially treated with oral voriconazole 400 mg twice a day on day 1, and then 200 mg twice daily for 12 weeks (BII).19 The optimal dose of voriconazole for secondary prophylaxis after 12 weeks has not been studied.
Special Considerations with Regard to Starting ART
No studies exist regarding the optimal time to start ART in HIV-infected patients with acute penicilliosis, but anecdotal experience and information from clinical trials on other HIV associated opportunistic infections suggests that in those with active penicilliosis who have CD4 counts ≤50 cells/mm3, ART should be started as soon as possible after the initiation of antifungal therapy (BIII). In patients with CD4 counts >50 cells/mm3, it may be prudent to delay initiation of ART until after completion of the first 2 weeks of induction therapy for penicilliosis (CIII).
Monitoring of Response to Therapy and Adverse Events (Including IRIS)
Patients treated with amphotericin B should be monitored for dose-dependent nephrotoxicity and electrolyte disturbances. Pre-infusion administration of 500 to 1000 mL of normal saline reduces the risk of nephrotoxicity during treatment (BII). Infusion-related adverse reactions can be ameliorated by pretreatment with acetaminophen and diphenhydramine.
Because absorption of itraconazole can be erratic and because itraconazole can interact with some antiretroviral drugs, serum itraconazole levels should be obtained in all patients to ensure adequate drug exposure (AIII). The serum concentration should be >1 µg/mL. Itraconazole solution is recommended over the capsule formulation because of better bioavailability, but this has not been studied specifically in AIDS patients.
Azoles and antiretroviral drugs such as protease ihibitors (PIs) and non-nucleoside reverse transciptase inhibitors (NNRTIs) do interact (see Table 5). Through the CYP3A4 mechanism, itraconazole and voriconazole can increase blood levels and effects of PIs and NNRTIs. On the other hand, NNRTIs can slightly decrease blood levels of itraconazole and voriconazole. Close monitoring should be done when using these drugs together.
The unmasking type of immune reconstitution inflammatory syndrome (IRIS) has been reported in several patients with penicilliosis.20,21 No paradoxical IRIS responses have been reported when ART is initiated in patients with established penicilliosis. ART should not be withheld because of concern for possible development of IRIS (AIII).
Managing Treatment Failure
Voriconazole has been reported to have good outcomes and can be used in patients whose infections fail to respond to initial therapy with amphotericin B followed by itraconazole (BII).19
When To Start Secondary Prophylaxis
A study showed that more than 50% of patients not treated with ART had relapse of P. marneffei within 6 months after discontinuation of antifungal therapy.18,22 A double-blind, placebo-controlled study from Chiang Mai, Thailand, demonstrated that oral itraconazole 200 mg daily for secondary prophylaxis in AIDS patients, reduced the relapse rate for P. marneffei from 57% to 0% (P < 0.001).22 All patients who successfully complete treatment for penicilliosis should receive secondary prophylaxis (chronic maintenance therapy) with oral itraconazole 200 mg/day (AI) and should be started on ART if that was not done during acute disease (AIII).
When To Stop Secondary Prophylaxis
No randomized, controlled study has demonstrated the safety of discontinuation of secondary prophylaxis for penicilliosis. However, a retrospective cohort study reported no relapse of penicilliosis after discontinuation of itraconazole in patients receiving ART whose CD4 cell counts were >100 cells/mm3.16 Therefore, secondary prophylaxis for penicilliosis can be discontinued in AIDS patients who receive combination ART and have CD4 cell counts >100 cells/mm3 for at least 6 months (BII). Secondary prophylaxis should be reintroduced if the CD4 cell count decreases to <100 cells/mm3 (AIII)
Special Considerations During Pregnancy
Diagnosis and treatment of penicilliosis during pregnancy are similar to those in non-pregnant adults, with the following considerations regarding antifungal use in pregnancy. Amphotericin B has not been shown to be teratogenic in animals, and no increase in anomalies has been seen with its use in humans. Neonates born to women on chronic amphotericin B at delivery should be evaluated for renal dysfunction and hypokalemia.
Itraconazole has been shown to be teratogenic in animals at high doses, but the metabolic mechanism accounting for these defects is not present in humans, so the data are not applicable. Case series in humans do not suggest an increased risk of birth defects with itraconazole, but experience is very limited. Voriconazole is Food and Drug Administration category D because of cleft palate and renal defects seen in rats and embryotoxicity in rabbits. No human data on use of voriconazole are available, so use in the first trimester is not recommended. No evidence of birth defects has been seen after episodic exposure to single, 150-mg doses of fluconazole. With chronic use of doses ≥400 mg in pregnancy, however, 5 cases of a syndrome of craniosynostosis, characteristic facies, digital synostosis, and limb contractures have been reported (fluconazole embryopathy).23
Substitution of amphotericin B for high-dose azoles in the first trimester is recommended (BIII). Women on secondary prophylaxis with itraconazole or other azoles should postpone pregnancy until their CD4 cell counts have been restored with ART, such that prophylaxis can be discontinued (BIII).
|Preventing 1st Episode of Penicilliosis (Primary Prophylaxis)
Indication for Primary Prophylaxis:
|Treating Acute Infection in Severely Ill Patients
|Chronic Maintenance Therapy (Secondary Prophylaxis)
a Both itraconazole and voriconazole can have significant drug-drug interactions with various ARV drugs, dosage adjustment may be necessary, consider therapeutic drug monitoring to guide therapy. See Table 5 for drug interaction information
Key to Acronyms: CD4 = CD4 T lymphocyte; PO = orally; IV = intravenous; q(n)h = every “n” hours; BID = twice daily; ART = antiretroviral therapy, ARV = antriretroviral
- Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet. Jul 9 1994;344(8915):110-113. Available at http://www.ncbi.nlm.nih.gov/pubmed/7912350.
- Clezy K, Sirisanthana T, Sirisanthana V, Brew B, Cooper DA. Late manifestations of HIV in Asia and the Pacific. AIDS. 1994;8 Suppl 2(Suppl 2):S35-43. Available at http://www.ncbi.nlm.nih.gov/pubmed/7857567.
- Kantipong P, Panich V, Pongsurachet V, Watt G. Hepatic penicilliosis in patients without skin lesions. Clin Infect Dis. May 1998;26(5):1215-1217. Available at http://www.ncbi.nlm.nih.gov/pubmed/9597255.
- Singh PN, Ranjana K, Singh YI, et al. Indigenous disseminated Penicillium marneffei infection in the state of Manipur, India: report of four autochthonous cases. J Clin Microbiol. Aug 1999;37(8):2699-2702. Available at http://www.ncbi.nlm.nih.gov/pubmed/10405425.
- Ranjana KH, Priyokumar K, Singh TJ, et al. Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect. Nov 2002;45(4):268-271. Available at http://www.ncbi.nlm.nih.gov/pubmed/12423616.
- Devi SB, Devi TS, Ningshen R, Devi Kh R, Singh TB, Singh NB. Penicillium morneffei, an emerging AIDS-related pathogen--a RIMS study. J Indian Med Assoc. Apr 2009;107(4):208-210. Available at http://www.ncbi.nlm.nih.gov/pubmed/19810362.
- Chariyalertsak S, Sirisanthana T, Saengwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994--1998: regional variation and temporal trends. Clin Infect Dis. Mar 15 2001;32(6):955-962. Available at http://www.ncbi.nlm.nih.gov/pubmed/11247718.
- Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis. Jan 15 2002;34(2):277-284. Available at http://www.ncbi.nlm.nih.gov/pubmed/11740718.
- Supparatpinyo K, Nelson KE, Merz WG, et al. Response to antifungal therapy by human immunodeficiency virus-infected patients with disseminated Penicillium marneffei infections and in vitro susceptibilities of isolates from clinical specimens. Antimicrob Agents Chemother. Nov 1993;37(11):2407-2411. Available at http://www.ncbi.nlm.nih.gov/pubmed/8285625.
- Chariyalertsak S, Sirisanthana T, Supparatpinyo K, Nelson KE. Seasonal variation of disseminated Penicillium marneffei infections in northern Thailand: a clue to the reservoir? J Infect Dis. Jun 1996;173(6):1490-1493. Available at http://www.ncbi.nlm.nih.gov/pubmed/8648227.
- Le T, Wolbers M, Chi NH, et al. Epidemiology, seasonality, and predictors of outcome of AIDS-associated Penicillium marneffei infection in Ho Chi Minh City, Viet Nam. Clin Infect Dis. Apr 1 2011;52(7):945-952. Available at http://www.ncbi.nlm.nih.gov/pubmed/21427403.
- Vanittanakom N, Cooper CR, Jr., Fisher MC, Sirisanthana T. Penicillium marneffei infection and recent advances in the epidemiology and molecular biology aspects. Clin Microbiol Rev. Jan 2006;19(1):95-110. Available at http://www.ncbi.nlm.nih.gov/pubmed/16418525.
- Supparatpinyo K, Sirisanthana T. Disseminated Penicillium marneffei infection diagnosed on examination of a peripheral blood smear of a patient with human immunodeficiency virus infection. Clin Infect Dis. Feb 1994;18(2):246-247. Available at http://www.ncbi.nlm.nih.gov/pubmed/8161635.
- Chaiwarith R, Fakthongyoo A, Praparattanapan J, Boonmee D, Sirisanthana T, Supparatpinyo K. Itraconazole vs fluconazole as a primary prophylaxis for fungal infections in HIV-infected patients in Thailand. Curr HIV Res. Jul 2011;9(5):334-338. Available at http://www.ncbi.nlm.nih.gov/pubmed/21916838.
- Hilmarsdottir I, Coutellier A, Elbaz J, et al. A French case of laboratory-acquired disseminated Penicillium marneffei infection in a patient with AIDS. Clin Infect Dis. Aug 1994;19(2):357-358. Available at http://www.ncbi.nlm.nih.gov/pubmed/7986922.
- Chaiwarith R, Charoenyos N, Sirisanthana T, Supparatpinyo K. Discontinuation of secondary prophylaxis against penicilliosis marneffei in AIDS patients after HAART. AIDS. Jan 30 2007;21(3):365-367. Available at http://www.ncbi.nlm.nih.gov/pubmed/17255744.
- Sirisanthana T, Supparatpinyo K, Perriens J, Nelson KE. Amphotericin B and itraconazole for treatment of disseminated Penicillium marneffei infection in human immunodeficiency virus-infected patients. Clin Infect Dis. May 1998;26(5):1107-1110. Available at http://www.ncbi.nlm.nih.gov/pubmed/9597237.
- Supparatpinyo K, Chiewchanvit S, Hirunsri P, et al. An efficacy study of itraconazole in the treatment of Penicillium marneffei infection. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. Dec 1992;75(12):688-691. Available at http://www.ncbi.nlm.nih.gov/pubmed/1339213.
- Supparatpinyo K, Schlamm HT. Voriconazole as therapy for systemic Penicillium marneffei infections in AIDS patients. Am J Trop Med Hyg. Aug 2007;77(2):350-353. Available at http://www.ncbi.nlm.nih.gov/pubmed/17690411.
- Manosuthi W, Chaovavanich A, Tansuphaswadikul S, et al. Incidence and risk factors of major opportunistic infections after initiation of antiretroviral therapy among advanced HIV-infected patients in a resource-limited setting. J Infect. Nov 2007;55(5):464-469. Available at http://www.ncbi.nlm.nih.gov/pubmed/17714788.
- Gupta S, Mathur P, Maskey D, Wig N, Singh S. Immune restoration syndrome with disseminated Penicillium marneffei and cytomegalovirus co-infections in an AIDS patient. AIDS Res Ther. 2007;4:21. Available at http://www.ncbi.nlm.nih.gov/pubmed/17922912.
- Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human immunodeficiency virus. N Engl J Med. Dec 10 1998;339(24):1739-1743. Available at http://www.ncbi.nlm.nih.gov/pubmed/9845708.
- Lopez-Rangel E, Van Allen MI. Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. Birth defects research. Part A, Clinical and molecular teratology. Nov 2005;73(11):919-923. Available at http://www.ncbi.nlm.nih.gov/pubmed/16265639.
- CDC | 2015 STD Treatment Guidelines
- HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
- AIDSinfo Patient Materials: What is an Opportunistic Infection?
- AIDSource | HIV-Related Conditions
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Adult and Adolescent OI Guidelines Archive